Log in

Aquinox Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:AQXP)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$3.68
MA: $3.94
$4.03
52-Week Range N/A
Volume266,735 shs
Average Volume239,362 shs
Market Capitalization$94.87 million
P/E RatioN/A
Dividend YieldN/A
Beta-7.37
Aquinox Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AQXP
CUSIPN/A
Phone604-629-9223

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$25 million
Book Value$3.09 per share

Profitability

Net Income$-31,580,000.00

Miscellaneous

Employees8
Market Cap$94.87 million
Next Earnings DateN/A
OptionableOptionable

Receive AQXP News and Ratings via Email

Sign-up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.


Aquinox Pharmaceuticals (NASDAQ:AQXP) Frequently Asked Questions

What is Aquinox Pharmaceuticals' stock symbol?

Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."

How were Aquinox Pharmaceuticals' earnings last quarter?

Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) posted its earnings results on Thursday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.43. View Aquinox Pharmaceuticals' Earnings History.

Has Aquinox Pharmaceuticals been receiving favorable news coverage?

Media headlines about AQXP stock have been trending positive this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Aquinox Pharmaceuticals.

Who are some of Aquinox Pharmaceuticals' key competitors?

What other stocks do shareholders of Aquinox Pharmaceuticals own?

Who are Aquinox Pharmaceuticals' key executives?

Aquinox Pharmaceuticals' management team includes the folowing people:
  • Mr. David J. Main, Co-Founder, Chairman, CEO & Pres (Age 54)
  • Mr. Kamran Alam, CFO, VP of Fin. & Corp. Sec. (Age 45)
  • Ms. Shelley McCloskey, VP of HR & Admin. (Age 59)

How big of a company is Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals has a market capitalization of $0.00 and generates $25 million in revenue each year. Aquinox Pharmaceuticals employs 8 workers across the globe.View Additional Information About Aquinox Pharmaceuticals.

What is Aquinox Pharmaceuticals' official website?

The official website for Aquinox Pharmaceuticals is http://www.aqxpharma.com/.

How can I contact Aquinox Pharmaceuticals?

Aquinox Pharmaceuticals' mailing address is 450-887 GREAT NORTHERN WAY, VANCOUVER A1, V5T 4T5. The company can be reached via phone at 604-629-9223 or via email at [email protected]


MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  216 (Vote Underperform)
Total Votes:  491
MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe AQXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AQXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel